BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 24924168)

  • 1. Receptor tyrosine kinases in osteosarcoma: not just the usual suspects.
    Rettew AN; Getty PJ; Greenfield EM
    Adv Exp Med Biol; 2014; 804():47-66. PubMed ID: 24924168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells.
    Kim D; Bach DH; Fan YH; Luu TT; Hong JY; Park HJ; Lee SK
    Cell Death Dis; 2019 May; 10(5):361. PubMed ID: 31043587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors.
    Linger RM; Keating AK; Earp HS; Graham DK
    Expert Opin Ther Targets; 2010 Oct; 14(10):1073-90. PubMed ID: 20809868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exosome-transmitted linc00852 associated with receptor tyrosine kinase AXL dysregulates the proliferation and invasion of osteosarcoma.
    Li Q; Wang X; Jiang N; Xie X; Liu N; Liu J; Shen J; Peng T
    Cancer Med; 2020 Sep; 9(17):6354-6366. PubMed ID: 32673448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bufalin down-regulates Axl expression to inhibit cell proliferation and induce apoptosis in non-small-cell lung cancer cells.
    Kim NY; Suh YA; Kim S; Lee C
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32219334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TAS-115 inhibits PDGFRα/AXL/FLT-3 signaling and suppresses lung metastasis of osteosarcoma.
    Yasuda N; Takenaka S; Nakai S; Nakai T; Yamada S; Imura Y; Outani H; Hamada K; Yoshikawa H; Naka N
    FEBS Open Bio; 2020 May; 10(5):767-779. PubMed ID: 32128992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knockdown of AXL receptor tyrosine kinase in osteosarcoma cells leads to decreased proliferation and increased apoptosis.
    Zhang Y; Tang YJ; Man Y; Pan F; Li ZH; Jia LS
    Int J Immunopathol Pharmacol; 2013; 26(1):179-88. PubMed ID: 23527720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor Tyrosine Kinases in Osteosarcoma: 2019 Update.
    Greenfield EM; Collier CD; Getty PJ
    Adv Exp Med Biol; 2020; 1258():141-155. PubMed ID: 32767239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of the metastatic spread of breast cancer by DN10764 (AZD7762)-mediated inhibition of AXL signaling.
    Park JS; Lee C; Kim HK; Kim D; Son JB; Ko E; Cho JH; Kim ND; Nan HY; Kim CY; Yoon S; Lee SH; Choi HG
    Oncotarget; 2016 Dec; 7(50):83308-83318. PubMed ID: 27829217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
    Rho JK; Choi YJ; Kim SY; Kim TW; Choi EK; Yoon SJ; Park BM; Park E; Bae JH; Choi CM; Lee JC
    Cancer Res; 2014 Jan; 74(1):253-62. PubMed ID: 24165158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wnt signaling in osteosarcoma.
    Lin CH; Ji T; Chen CF; Hoang BH
    Adv Exp Med Biol; 2014; 804():33-45. PubMed ID: 24924167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients.
    Han J; Tian R; Yong B; Luo C; Tan P; Shen J; Peng T
    Biochem Biophys Res Commun; 2013 Jun; 435(3):493-500. PubMed ID: 23684620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. lncRNA DANCR promotes tumor progression and cancer stemness features in osteosarcoma by upregulating AXL via miR-33a-5p inhibition.
    Jiang N; Wang X; Xie X; Liao Y; Liu N; Liu J; Miao N; Shen J; Peng T
    Cancer Lett; 2017 Oct; 405():46-55. PubMed ID: 28642170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER-2 involvement in osteosarcoma.
    Gill J; Geller D; Gorlick R
    Adv Exp Med Biol; 2014; 804():161-77. PubMed ID: 24924174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer.
    Yeh CY; Shin SM; Yeh HH; Wu TJ; Shin JW; Chang TY; Raghavaraju G; Lee CT; Chiang JH; Tseng VS; Lee YC; Shen CH; Chow NH; Liu HS
    BMC Cancer; 2011 Apr; 11():139. PubMed ID: 21496277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axl Receptor Axis: A New Therapeutic Target in Lung Cancer.
    Levin PA; Brekken RA; Byers LA; Heymach JV; Gerber DE
    J Thorac Oncol; 2016 Aug; 11(8):1357-1362. PubMed ID: 27130831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines.
    Rettew AN; Young ED; Lev DC; Kleinerman ES; Abdul-Karim FW; Getty PJ; Greenfield EM
    Oncogenesis; 2012 Nov; 1(11):e34. PubMed ID: 23552467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of ezrin in osteosarcoma metastasis.
    Ren L; Khanna C
    Adv Exp Med Biol; 2014; 804():181-201. PubMed ID: 24924175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of the phenylpyrazolo[3,4-
    Lee HJ; Pham PC; Pei H; Lim B; Hyun SY; Baek B; Kim B; Kim Y; Kim MH; Kang NW; Min HY; Kim DD; Lee J; Lee HY
    Theranostics; 2021; 11(4):1918-1936. PubMed ID: 33408789
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting Axl and Mer kinases in cancer.
    Verma A; Warner SL; Vankayalapati H; Bearss DJ; Sharma S
    Mol Cancer Ther; 2011 Oct; 10(10):1763-73. PubMed ID: 21933973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.